Valuation: Ardelyx, Inc.

Market Cap 752M 670M 613M 558M 1.05B 71.03B 1.08B 7.36B 2.94B 37.62B 2.82B 2.76B 119B P/E 2026 *
-16.3x
P/E 2027 * 12.3x
Enterprise Value 752M 670M 613M 558M 1.05B 71.03B 1.08B 7.36B 2.94B 37.62B 2.82B 2.76B 119B EV / Sales 2026 *
1.56x
EV / Sales 2027 * 1.21x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day-9.12%
1 week-3.55%
Current month-1.32%
1 month-11.80%
3 months-39.10%
6 months-58.06%
Current year-48.71%
1 week 2.96
Extreme 2.96
3.41
1 month 2.96
Extreme 2.955
3.41
Current year 2.96
Extreme 2.955
8.4
1 year 2.96
Extreme 2.955
8.4
3 years 2.96
Extreme 2.955
10.13
5 years 0.49
Extreme 0.4902
10.13
10 years 0.49
Extreme 0.4902
16.3
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2009
Director of Finance/CFO 55 04/11/2025
Chief Tech/Sci/R&D Officer 50 01/04/2026
Director TitleAgeSince
Director/Board Member 61 01/03/2009
Chairman 60 01/03/2014
Director/Board Member 59 01/03/2014
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 A Sell

Chief Financial Officer

-1,558 0.0006%
8/21/26 A Sell

Controller/Auditor

-3,982 0.0016%
8/21/26 A Sell

Head of Human Resources

-15,136 0.0061%
Change 5-day change 1-year change 3-year change Capi.($)
-9.12%-3.55%-49.75%-25.62% 752M
+3.80%+8.10%+63.78%+77.70% 69.4B
+0.07%+1.39%+12.75%+75.17% 57.24B
+1.63%+4.93%+24.89%+104.31% 57.62B
+0.41%-3.70%+26.06%+34.32% 43.65B
+2.51%+4.22%+20.49%+110.71% 44.03B
-11.04%-6.63%+199.38%+701.67% 38.08B
+7.50%+13.58%+29.07%+64.46% 36.31B
+1.59%-4.04%+97.66%+79.95% 32.61B
-1.60%+7.55%+36.69%-4.51% 25.47B
Average -0.44%+2.16%+46.10%+121.82% 40.52B
Weighted average by Cap. +0.85%+3.10%+52.72%+132.32%

Financials

2026 *2027 *
Net sales 482M 430M 393M 358M 675M 45.58B 693M 4.72B 1.89B 24.14B 1.81B 1.77B 76.18B 621M 554M 506M 461M 869M 58.72B 893M 6.08B 2.43B 31.1B 2.33B 2.28B 98.13B
Net income -44.04M -39.24M -35.89M -32.69M -61.62M -4.16B -63.28M -431M -172M -2.2B -165M -162M -6.95B 66.62M 59.36M 54.3M 49.45M 93.21M 6.3B 95.72M 652M 261M 3.33B 250M 245M 10.52B
Net Debt - -
Projected Income Statement - Annual - Ardelyx, Inc.
Logo Ardelyx, Inc.
Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.
Employees
489
Date Price Change Volume
05/11/26 $2.990 -9.12% 7,766,728
04/11/26 $3.290 +8.58% 10,874,644
03/11/26 $3.030 0.00% 6,218,043
02/11/26 $3.030 0.00% 4,612,219
30/10/26 $3.030 -2.26% 3,625,878
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ardelyx, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
2.990USD
Average target price
12.80USD
Spread / Average Target
+328.09%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ardelyx, Inc.
  1. Stock Market
  2. Stocks
  3. ARDX Stock